Jazz Pharmaceuticals(US:JAZZ) Prnewswire·2025-12-05 14:00Core Insights - Jazz Pharmaceuticals announced the presentation of eight abstracts, including four late-breaking ones, at the American Epilepsy Society (AES) 2025 Annual Meeting, focusing on the efficacy of Epidiolex (cannabidiol) in treating rare forms of epilepsy [1][2][3] Group 1: EpiCom Trial Results - The EpiCom trial, a Phase 3b/4 study, showed promising reductions in behavioral problems associated with tuberous sclerosis complex (TSC) after 26 weeks of Epidiolex treatment, as indicated by improvements in TAND-SQ and ABC subscale scores [2][3] - The trial utilized novel endpoints that focused on individualized outcomes, addressing the specific problematic behaviors identified by caregivers and clinicians [3] Group 2: Additional Highlights from AES 2025 - A late-breaking poster presented results from a Phase 1 study that found no pharmacokinetic interactions between Epidiolex and cenobamate when administered together [4] - Preclinical data demonstrated a novel synergistic pharmacodynamic interaction between Epidiolex and cenobamate in a mouse model of seizures [4] - Real-world effectiveness data indicated that initiating Epidiolex in CBD-naïve patients with Dravet Syndrome, Lennox-Gastaut Syndrome, or TSC led to reduced polypharmacy and healthcare resource utilization after 12 months [4] - A post-hoc analysis from the Expanded Access Program showed that Epidiolex treatment was associated with reductions in seizure frequency in patients with developmental and epileptic encephalopathies [4] Group 3: Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing innovative medicines for serious diseases, including epilepsy, with a commitment to addressing the needs of patients with limited therapeutic options [21]